Neoleukin Therapeutics

Neoleukin Therapeutics: Lead program NL-201: is a dual-acting IL-2 and IL-15 agonist immunotherapy for cancer, designed to improve tolerability and activity by eliminating the alpha receptor binding interface (IND completed 4Q20). First de novo protein therapeutic ever created.
Healthcare/Drug Manufacturers
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Allergy, Autoimmune, Immuno-Oncology, Infectious Disease, Oncology
Public, USA
Market Cap
500MM - 1B
1616 Eastlake Avenue E
Suit 360
Seattle, WA 98109
United States

Company Participants at Neoleukin Investor R&D Showcase - AACR 2020 (Virtual)

  • Jonathan G. Drachman, CEO

Top 10 Holders of Neoleukin Therapeutics, Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Redmile Group LLC 8.58 4,172,686 55.66 13F 9/30/20
Ecor1 Capital LLC 7.94 3,862,931 51.53 13F 9/30/20
Baker Bros. Advisors LP 7.86 3,821,740 50.98 13F 9/30/20
Pictet Asset Management Ltd. 4.24 2,061,283 27.50 13F 9/30/20
Boxer Capital LLC 3.09 1,501,058 20.02 13F 9/30/20
Opaleye Management, Inc. 2.85 1,386,300 18.49 13F 9/30/20
The Vanguard Group, Inc. 2.40 1,168,191 15.58 Funds 12/31/20
BlackRock Fund Advisors 2.23 1,084,591 14.47 13F 9/30/20
Point72 Asset Management LP (Old) 2.06 999,694 13.34 13F 9/30/20
Vanguard Group, Inc. (Subfiler) 2.05 995,253 13.28 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.